TY - JOUR
T1 - Progress in the development of melanocortin receptor selective ligands
AU - Irani, Boman G.
AU - Holder, Jerry R.
AU - Todorovic, Aleksandar
AU - Wilczynski, Andrzej M.
AU - Joseph, Christine G.
AU - Wilson, Krista R.
AU - Haskell-Luevano, Carrie
PY - 2004
Y1 - 2004
N2 - The melanocortin pathway consists of endogenous agonists, antagonists, G-protein coupled receptors (GPCRs), and auxiliary proteins. This pathway has been identified to participate physiologically in numerous biological pathways including energy homeostasis, pigmentation, sexual function, inflammation, cardiovascular function, adrenal function, sebaceous gland lipid production, just to list a few. During this past decade, a clear link between the melanocortin-4 receptor (MC4R) and obesity, in both mice and humans via the regulation of food intake and energy homeostasis, has made this pathway the target of many academic and industrial research endeavors in attempts to develop potent and selective MC4R small molecules as anti-obesity therapeutic agents. Herein, we attempt to summarize the known proteins that constitute the melanocortin system and discuss advances in peptide and non-peptide drug discovery.
AB - The melanocortin pathway consists of endogenous agonists, antagonists, G-protein coupled receptors (GPCRs), and auxiliary proteins. This pathway has been identified to participate physiologically in numerous biological pathways including energy homeostasis, pigmentation, sexual function, inflammation, cardiovascular function, adrenal function, sebaceous gland lipid production, just to list a few. During this past decade, a clear link between the melanocortin-4 receptor (MC4R) and obesity, in both mice and humans via the regulation of food intake and energy homeostasis, has made this pathway the target of many academic and industrial research endeavors in attempts to develop potent and selective MC4R small molecules as anti-obesity therapeutic agents. Herein, we attempt to summarize the known proteins that constitute the melanocortin system and discuss advances in peptide and non-peptide drug discovery.
UR - http://www.scopus.com/inward/record.url?scp=5744254369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5744254369&partnerID=8YFLogxK
U2 - 10.2174/1381612043382891
DO - 10.2174/1381612043382891
M3 - Review article
C2 - 15579046
AN - SCOPUS:5744254369
SN - 1381-6128
VL - 10
SP - 3443
EP - 3479
JO - Current pharmaceutical design
JF - Current pharmaceutical design
IS - 28
ER -